RenovaCare, Inc. (RCAR)
USD 0.0
(-50.0%)
USD 0.0
(-50.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2022 | - USD | 100.0% |
| 2021 | -2.81 Million USD | 61.56% |
| 2020 | -7.33 Million USD | 39.82% |
| 2019 | -12.18 Million USD | 20.86% |
| 2018 | -15.39 Million USD | -723.54% |
| 2017 | -1.86 Million USD | -640.32% |
| 2016 | -252.55 Thousand USD | 36.48% |
| 2015 | -397.58 Thousand USD | 41.8% |
| 2014 | -683.09 Thousand USD | 54.73% |
| 2013 | -1.5 Million USD | -193.78% |
| 2012 | -513.59 Thousand USD | 34.8% |
| 2011 | -787.77 Thousand USD | 61.62% |
| 2010 | -2.05 Million USD | 14.83% |
| 2009 | -2.4 Million USD | 11.88% |
| 2008 | -2.73 Million USD | -5805.48% |
| 2007 | -46.3 Thousand USD | -25914.61% |
| 2006 | -178.00 USD | 99.78% |
| 2005 | -81.97 Thousand USD | 36.1% |
| 2004 | -128.28 Thousand USD | 56.1% |
| 2003 | -292.19 Thousand USD | 64.45% |
| 2002 | -821.86 Thousand USD | 0.57% |
| 2001 | -826.6 Thousand USD | 11.89% |
| 2000 | -938.14 Thousand USD | 50.77% |
| 1999 | -1.9 Million USD | -55.51% |
| 1998 | -1.22 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q3 | - USD | 0.0% |
| 2023 Q1 | - USD | 0.0% |
| 2023 Q2 | - USD | 0.0% |
| 2022 Q2 | 556.04 Thousand USD | 152.84% |
| 2022 Q1 | -1.05 Million USD | 62.67% |
| 2022 FY | - USD | 100.0% |
| 2022 Q3 | 699.26 Thousand USD | 25.76% |
| 2022 Q4 | - USD | -100.0% |
| 2021 Q2 | -4.28 Million USD | 22.61% |
| 2021 FY | -2.81 Million USD | 61.56% |
| 2021 Q4 | -2.81 Million USD | 16.57% |
| 2021 Q3 | -3.37 Million USD | 21.2% |
| 2021 Q1 | -5.54 Million USD | 24.45% |
| 2020 Q3 | -8.58 Million USD | 16.31% |
| 2020 Q4 | -7.33 Million USD | 14.58% |
| 2020 FY | -7.33 Million USD | 39.82% |
| 2020 Q2 | -10.25 Million USD | 9.88% |
| 2020 Q1 | -11.38 Million USD | 6.59% |
| 2019 Q2 | -14.27 Million USD | 4.49% |
| 2019 Q4 | -12.18 Million USD | 8.89% |
| 2019 Q1 | -14.94 Million USD | 2.95% |
| 2019 Q3 | -13.37 Million USD | 6.29% |
| 2019 FY | -12.18 Million USD | 20.86% |
| 2018 Q1 | -1.28 Million USD | 31.01% |
| 2018 Q4 | -15.39 Million USD | -2664.99% |
| 2018 Q3 | -556.87 Thousand USD | 35.13% |
| 2018 Q2 | -858.49 Thousand USD | 33.44% |
| 2018 FY | -15.39 Million USD | -723.54% |
| 2017 Q2 | 142.66 Thousand USD | 176.58% |
| 2017 Q4 | -1.86 Million USD | -462.59% |
| 2017 Q3 | -332.33 Thousand USD | -332.95% |
| 2017 Q1 | -186.28 Thousand USD | 26.24% |
| 2017 FY | -1.86 Million USD | -640.32% |
| 2016 Q3 | -656.99 Thousand USD | -137.91% |
| 2016 Q1 | -837.91 Thousand USD | -110.75% |
| 2016 Q2 | -276.14 Thousand USD | 67.04% |
| 2016 Q4 | -252.55 Thousand USD | 61.56% |
| 2016 FY | -252.55 Thousand USD | 36.48% |
| 2015 Q2 | -1.16 Million USD | -213.66% |
| 2015 Q3 | -905.89 Thousand USD | 22.08% |
| 2015 Q4 | -397.58 Thousand USD | 56.11% |
| 2015 FY | -397.58 Thousand USD | 41.8% |
| 2015 Q1 | -370.64 Thousand USD | 45.74% |
| 2014 Q2 | -1.16 Million USD | 13.43% |
| 2014 Q3 | -889.79 Thousand USD | 23.82% |
| 2014 FY | -683.09 Thousand USD | 54.73% |
| 2014 Q4 | -683.09 Thousand USD | 23.23% |
| 2014 Q1 | -1.34 Million USD | 10.58% |
| 2013 Q2 | -392.17 Thousand USD | 19.97% |
| 2013 FY | -1.5 Million USD | -193.78% |
| 2013 Q4 | -1.5 Million USD | -539.07% |
| 2013 Q1 | -490.05 Thousand USD | 4.58% |
| 2013 Q3 | -236.09 Thousand USD | 39.8% |
| 2012 Q3 | -578.1 Thousand USD | 4.07% |
| 2012 Q2 | -602.65 Thousand USD | 8.87% |
| 2012 Q4 | -513.59 Thousand USD | 11.16% |
| 2012 FY | -513.59 Thousand USD | 34.8% |
| 2012 Q1 | -661.3 Thousand USD | 16.05% |
| 2011 Q4 | -787.77 Thousand USD | 18.32% |
| 2011 Q2 | -1.13 Million USD | 41.08% |
| 2011 Q3 | -964.44 Thousand USD | 14.86% |
| 2011 FY | -787.77 Thousand USD | 61.62% |
| 2011 Q1 | -1.92 Million USD | 6.32% |
| 2010 Q2 | -2.26 Million USD | 2.43% |
| 2010 FY | -2.05 Million USD | 14.83% |
| 2010 Q4 | -2.05 Million USD | 5.89% |
| 2010 Q3 | -2.18 Million USD | 3.86% |
| 2010 Q1 | -2.32 Million USD | 3.52% |
| 2009 Q3 | -2.47 Million USD | 2.56% |
| 2009 Q1 | -2.66 Million USD | 2.55% |
| 2009 FY | -2.4 Million USD | 11.88% |
| 2009 Q2 | -2.53 Million USD | 4.87% |
| 2009 Q4 | -2.4 Million USD | 2.44% |
| 2008 Q3 | -2.85 Million USD | -18448.44% |
| 2008 FY | -2.73 Million USD | -5805.48% |
| 2008 Q4 | -2.73 Million USD | 4.38% |
| 2008 Q1 | -32.45 Thousand USD | 29.91% |
| 2008 Q2 | -15.41 Thousand USD | 52.49% |
| 2007 Q2 | -65.02 Thousand USD | 17.34% |
| 2007 FY | -46.3 Thousand USD | -25914.61% |
| 2007 Q1 | -78.66 Thousand USD | -44094.38% |
| 2007 Q4 | -46.3 Thousand USD | 19.49% |
| 2007 Q3 | -57.51 Thousand USD | 11.55% |
| 2006 Q4 | -178.00 USD | 99.29% |
| 2006 FY | -178.00 USD | 99.78% |
| 2006 Q1 | -61.8 Thousand USD | 24.61% |
| 2006 Q2 | -35.9 Thousand USD | 41.91% |
| 2006 Q3 | -24.93 Thousand USD | 30.54% |
| 2005 Q3 | -96.59 Thousand USD | 11.17% |
| 2005 FY | -81.97 Thousand USD | 36.1% |
| 2005 Q4 | -81.97 Thousand USD | 15.13% |
| 2005 Q2 | -108.73 Thousand USD | 5.63% |
| 2005 Q1 | -115.22 Thousand USD | 10.18% |
| 2004 Q4 | -128.28 Thousand USD | 7.42% |
| 2004 FY | -128.28 Thousand USD | 56.1% |
| 2004 Q2 | -180.73 Thousand USD | 12.76% |
| 2004 Q1 | -207.16 Thousand USD | 29.1% |
| 2004 Q3 | -138.57 Thousand USD | 23.33% |
| 2003 Q2 | -511 Thousand USD | 23.11% |
| 2003 Q3 | -392.41 Thousand USD | 23.21% |
| 2003 Q4 | -292.19 Thousand USD | 25.54% |
| 2003 FY | -292.19 Thousand USD | 64.45% |
| 2003 Q1 | -664.62 Thousand USD | 19.13% |
| 2002 Q3 | -756.03 Thousand USD | 18.09% |
| 2002 FY | -821.86 Thousand USD | 0.57% |
| 2002 Q4 | -821.86 Thousand USD | -8.71% |
| 2002 Q1 | -881.57 Thousand USD | -6.65% |
| 2002 Q2 | -922.98 Thousand USD | -4.7% |
| 2001 Q2 | -865.04 Thousand USD | 13.79% |
| 2001 Q1 | -1 Million USD | -6.96% |
| 2001 Q3 | -526.48 Thousand USD | 39.14% |
| 2001 Q4 | -826.6 Thousand USD | -57.0% |
| 2001 FY | -826.6 Thousand USD | 11.89% |
| 2000 Q2 | -1.55 Million USD | 10.06% |
| 2000 FY | -938.14 Thousand USD | 50.77% |
| 2000 Q3 | -1.15 Million USD | 25.56% |
| 2000 Q4 | -938.14 Thousand USD | 18.95% |
| 2000 Q1 | -1.72 Million USD | 0.0% |
| 1999 FY | -1.9 Million USD | -55.51% |
| 1998 FY | -1.22 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 100.0% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 100.0% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 100.0% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 100.0% |
| Rebus Holdings, Inc. | 305 Thousand USD | 100.0% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 100.0% |
| Qrons Inc. | 351.42 Thousand USD | 100.0% |
| Adynxx, Inc. | - USD | NaN% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 100.0% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 100.0% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 100.0% |
| Skye Bioscience, Inc. | -5.72 Million USD | 100.0% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 100.0% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 100.0% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 100.0% |
| SQZ Biotechnologies Company | -36.23 Million USD | 100.0% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 100.0% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 100.0% |
| Mesoblast Limited | 55.85 Million USD | 100.0% |
| Marizyme, Inc. | 18.56 Million USD | 100.0% |
| Genus plc | 190.6 Million USD | 100.0% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 100.0% |
| Pharming Group N.V. | 109.8 Million USD | 100.0% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 100.0% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 100.0% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 100.0% |
| ContraFect Corporation | -6.02 Million USD | 100.0% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 100.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | NaN% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 100.0% |
| IMV Inc. | 7.67 Million USD | 100.0% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 100.0% |
| MultiCell Technologies, Inc. | 90.04 USD | 100.0% |
| ONE Bio Corp. | 9.04 Million USD | 100.0% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 100.0% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 100.0% |
| Arno Therapeutics, Inc. | - USD | NaN% |
| EV Biologics, Inc. | 1.36 Million USD | 100.0% |
| Q BioMed Inc. | 4.06 Million USD | 100.0% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 100.0% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 100.0% |
| Biomind Labs Inc. | 711.4 Thousand USD | 100.0% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 100.0% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 100.0% |
| TetraLogic Pharmaceuticals Corporation | - USD | NaN% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 100.0% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 100.0% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 100.0% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 100.0% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 100.0% |
| GB Sciences, Inc. | 1.74 Million USD | 100.0% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 100.0% |
| HST Global, Inc. | 96.79 Thousand USD | 100.0% |
| CSL Limited | 10.52 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 100.0% |
| Halberd Corporation | 144.72 Thousand USD | 100.0% |
| Enzolytics Inc. | 981.65 Thousand USD | 100.0% |
| Agentix Corp. | 37.63 Thousand USD | 100.0% |
| Resverlogix Corp. | 6.45 Million USD | 100.0% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 100.0% |
| MetaStat, Inc. | - USD | NaN% |
| argenx SE | -2.02 Billion USD | 100.0% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 100.0% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 100.0% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 100.0% |
| GeneThera, Inc. | - USD | NaN% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 100.0% |
| AVAX Technologies, Inc. | -5.9 Million USD | 100.0% |
| Zenith Capital Corp. | 10.06 Thousand USD | 100.0% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.0% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 100.0% |
| Anthera Pharmaceuticals, Inc. | - USD | NaN% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 100.0% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 100.0% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 100.0% |
| Kadimastem Ltd | -253.1 Thousand USD | 100.0% |
| Helix BioMedix, Inc. | -2.57 Million USD | 100.0% |
| VitaSpring Biomedical Co. Ltd. | - USD | NaN% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 100.0% |
| BioStem Technologies, Inc. | 4.47 Million USD | 100.0% |
| Oncology Pharma Inc. | - USD | NaN% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 100.0% |
| LadRx Corporation | -2.03 Million USD | 100.0% |
| Cell Source, Inc. | 9.23 Million USD | 100.0% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 100.0% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 100.0% |
| NovAccess Global Inc. | 2.17 Million USD | 100.0% |
| Affymax, Inc. | -5.59 Million USD | 100.0% |
| Itoco Inc. | 228.3 Thousand USD | 100.0% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 100.0% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 100.0% |
| Mobile Lads Corp. | 484.23 Thousand USD | 100.0% |
| CytoDyn Inc. | 20.26 Million USD | 100.0% |
| Claritas Pharmaceuticals, Inc. | - USD | NaN% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 100.0% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 100.0% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 100.0% |
| SYBLEU INC | 473.71 Thousand USD | 100.0% |
| Advanced Proteome Therapeutics Corporation | - USD | NaN% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 100.0% |
| International Stem Cell Corporation | 2.59 Million USD | 100.0% |
| Bioxytran, Inc. | 1.89 Million USD | 100.0% |
| GlobeImmune, Inc. | - USD | NaN% |
| Predictive Technology Group, Inc. | - USD | NaN% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 100.0% |
| Cardax, Inc. | - USD | NaN% |
| VG Life Sciences Inc. | 2.18 Million USD | 100.0% |
| Kaleido Biosciences, Inc. | - USD | NaN% |
| Advaxis, Inc. | 3.43 Million USD | 100.0% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 100.0% |
| Regnum Corp. | 772.6 Thousand USD | 100.0% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 100.0% |
| Neutra Corp. | 52.18 Thousand USD | 100.0% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 100.0% |
| PureTech Health plc | -167.19 Million USD | 100.0% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 100.0% |
| IXICO plc | -4.44 Million USD | 100.0% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 100.0% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 100.0% |
| CSL Limited | 10.52 Billion USD | 100.0% |
| Cellectis S.A. | -43.81 Million USD | 100.0% |